Treatment: patient groupRCTIncrementalICER (£ per QALY gained)Incremental net benefit
MonetaryHealth
Cost (£)Outcome (QALYs)λ = 20,000λ = 30,000λ = 20,000λ = 30,000
PEG α-2a: genotype 1Liu and colleagues53−4807−0.1434,51020076070.100.02
Yu and colleagues 200854−5212−0.0864,880452647220.180.09
PEG α-2b: genotype 1Berg and colleagues59−89960.49−18,35918,79623,6960.940.79
PEG α-2a: genotype 2 or 3Yu and colleagues55−21070.08−26,338370745070.190.15
von Wagner and colleagues 200854−31460.23−13,678428841760.390.33

PEG α, peginterferon alfa.

From: Appendix 8, Net benefit framework

Cover of Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation
Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.17.
Hartwell D, Jones J, Baxter L, et al.
Southampton (UK): NIHR Journals Library; 2011 Apr.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.